Alzheimer's Disease Research Center News

Stanford Alzheimer's Disease Research Center News

Why Should You Donate Your Brain To Science?

Can major surgery increase risk for Alzheimer’s disease?

Alzheimer’s Disease Research Center renamed for Asad Jamal, Iqbal Farrukh

Stanford researchers find signs of inflammation in brains of people who died of COVID-19

VJ Periyakoil Wins ABIM Foundation’s John A Benson Jr, MD Professionalism Article Prize

VJ Periyakoil, MD, professor of primary care and population health and associate dean of research for geriatrics and palliative care, just received the American Board in Internal Medicine or ABIM Foundation’s John A Benson Jr, MD Professionalism Article Prize for her article “Common Types of Gender-Based Microaggressions in Medicine.”

Failure to demonstrate efficacy of aducanumab

Researchers from Stanford University and the Mayo Clinic recently published a Perspective on the investigational drug aducanumab, which is under review by the Food and Drug Administration for the treatment of Alzheimer’s disease:  The authors state, “Aducanumab recently underwent two large phase III clinical trials that were stopped prematurely by the sponsor Biogen. One trial was trending positive while the other showed no benefits from aducanumab. Post hoc analyses led the sponsor to assert that there was a sufficient efficacy signal to justify a new drug application as a treatment for Alzheimer’s disease. The sponsor claimed that subsets of participants receiving sufficiently high doses of aducanumab demonstrated benefits in both trials. In contrast, we identified alternative accounts for the apparent drug benefits in post hoc subgroups that are unrelated to dose effects. Biomarker data were consistent with target engagement, but no evidence was presented to correlate biomarker changes to cognitive benefits. Our analysis supports the conduct of a third, phase III trial with high-dose aducanumab. Aducanumab’s efficacy as a treatment for the cognitive dysfunction in Alzheimer’s disease cannot be proven by clinical trials with divergent outcomes.”

Young Blood/Old Brains

National Institute on Aging awards $15 million to Stanford’s Alzheimer’s Disease Research Center

Negative Thinking Can Harm Your Brain and Increase Your Dementia Risk

Brain Health Registry featured on Asian Pacific America

Longevity Gene May Protect against a Notorious Alzheimer’s Risk Gene

Gene variant staves off Alzheimer’s in some people

Alzheimer’s Prevention and Preparedness Task Force

Suspicion: Why are virus-targeting immune cells sniffing around Alzheimer’s patients’ brains?

Thwarting A Protein Reverses Brain Decline in Aged Mice

Blocking protein curbs memory loss in old mice

Stanford team develops brain-rejuvenating antibodies that let old mice think like youngsters

Blocking protein’s activity restores cognition in old mice

Stanford announces new Lewy Body Dementia (LBD) Research Center of Excellence

Clearing clumps of protein in aging neural stem cells boosts their activity

Blood, the Secret Sauce? Focus on Plasma Promises AD Treatment

Scientists aim to wipe out dementia and other diseases of aging

Clinical trial finds blood-plasma infusions for Alzheimer’s safe, promising

Eight things you can do now that might reduce your odds of dementia later

Aging Research: Plasma Protein Revitalizes the Brain

Young human blood makes old mice smarter

Study shows protein in human umbilical cord blood rejuvenates old mice’s impaired learning, memory

Hack your brain to remember almost anything

Memorization tool bulks up brain's internal connections, scientists say

Stanford Brain Rejuvenation Project

Pilot study suggests therapy horses may aid people with dementia and their caregivers

The research team, led by Dolores Gallagher Thompson, PhD, and Nusha Askari, PhD, and Jacqueline Hartman at the Stanford Red Barn Leadership Program, found that supervised activities, such as observing herd behavior, grooming horses and leading horses with a lead and halter, helped participants recognize and use non-verbal forms of communication.

When It's Not Alzheimer's: The Differential Diagnosis of Frontotemporal Lobar Degeneration

Creative Minds: A New Chemistry for Aging Research?

Alzheimer's from a New Angle

The February 22, 2016 issue of Time Magazine covers the efforts of Dr. Longo and his team to develop a novel approach for Alzheimer’s therapy.  

Stanford neurologist ponders her interest in the human brain

As part of the team at the Stanford Center for Memory Disorders, Sha is dedicated to studying ways to fight memory disorders and cognitive decline. “I think it’s fascinating to help people understand why” the brain isn’t functioning in the right way, she shares.

5 Questions: Frank Longo on Alzheimer's, new neuroscience center

In a recent interview, neurologist Frank Longo discussed Alzheimer’s disease, recent research breakthroughs and the new Stanford Neuroscience Health Center, which he co-leads.

Scientists reverse the cognitive effects of aging in mice

A cure for aging? A scientist behind a breakthrough technique seems to have found a way to reverse cognitive ageing effects on mice. Next, is to find out if it will work on humans.

Can we reverse the ageing process by putting young blood into older people?

A series of experiments has produced incredible results by giving young blood to old mice. Now the findings are being tested on humans. Ian Sample meets the scientists whose research could transform our lives.

Alzheimer’s Disease: What Stands Between Us and a Cure?

Our understanding of Alzheimer’s disease is better than ever before. So why are we still so far from a cure?

What should we know about Alzheimer's disease?

In this Q&A, Michael Greicius discusses the causes, onset, progression and treatment of Alzheimer's disease. Greicius is an associate professor of neurology and neurological sciences and medical director of the Stanford Center for Memory Disorders.

Rejuvenating Old Brains with Young Blood | Tony Wyss-Coray | World Economic Forum

Might young blood be the fountain of youth? asks Tony Wyss-Coray from Stanford University. The Professor of Neurology says blood transports messages between different organs, and young blood may be able to boost health, recharge the old brain and halt cognitive decline.

Stanford to open Alzheimer's research center

A new Stanford ADRC will receive nearly $7.3 million in funding over a five-year period to conduct interdisciplinary research on Alzheimer’s disease and related disorders. Victor Henderson, professor of health research and policy and of neurology and neurological sciences, will direct the center; Tony Wyss-Coray, professor of neurology and neurological sciences, will serve as co-director; Frank Longo, the George E. and Lucy Becker Professor and professor and chair of neurology and neurological sciences and Jerome Yesavage, professor of psychiatry and behavioral sciences, will serve as associate directors; and Michael Greicius, associate professor of neurology, will lead the center's imaging core.

Stanford-based Alzheimer’s Disease Research Center to be launched

A new Stanford-based center will receive nearly $7.3 million in funding over a five-year period to conduct interdisciplinary research on Alzheimer’s disease and related disorders.  

Scientists find genetic underpinnings of functional brain networks seen in imaging studies

Imaging studies have delineated brain networks consisting of discrete brain regions acting in synchrony. This view of the brain’s functional architecture has now been confirmed by a study showing coordination at the genetic level as well. 

Talking about "mouseheimers," and a call for new neuroscience technologies

Michael Greicius, MD, MPH, professor of neurology & neurological sciences at Stanford, researches Alzheimer’s and has a bone to pick with media hype about Alzheimer’s research conducted in mice. What the mice have shouldn’t be considered the same condition, he says, so he’s termed it “mouseheimer’s.” 

Fighting to remember: U.S. Rep. Jackie Speier, experts host panel on Alzheimer’s disease

A panel of experts discussed Alzheimer's disease and its effects on women Monday in San Mateo. The panel included Michael Greicius, associate professor of neurology and neurological sciences and medical director of the Stanford Center for Memory Disorders, who is quoted here. 

The gene variant ApoE4 puts women at higher risk of Alzheimer's disease

The number of women with Alzheimer's far exceeds that of men with the condition. Researchers at Stanford University found that carrying a copy of a gene variant called ApoE4 puts women at a substantially higher risk for Alzheimer's disease than men. 

Are Women at Greater Risk for Alzheimer’s?

Neurologists Roberta Diaz Brinton and Michael Greicius discuss why it’s important to study women with Alzheimer’s as a distinct population, and why females might be more likely to develop the disease. 

Brain scientists speak at Davos economic forum

Members of research teams created through the Stanford Neurosciences Institute's Big Ideas in Neuroscience initiative spoke Jan. 23 at the World Economic Forum in Davos, Switzerland. 

Ageing research: Blood to blood

By splicing animals together, scientists have shown that young blood rejuvenates old tissues. Now, they are testing whether it works for humans.

Blocking receptor in brain’s immune cells counters Alzheimer’s in mice, study finds

Brain cells called microglia chew up toxic substances and cell debris, calm inflammation and make nerve-cell-nurturing substances. New research shows that keeping them on the job may prevent neurodegeneration. 

Can Alzheimer's damage to the brain be repaired?

Longo and his colleagues have pioneered the development of small-molecule drugs that might be able to restore nerve cells frayed by conditions such as Alzheimer’s.

Infusion of young blood recharges brains of old mice, study finds

Something in the blood of young mice has the ability to restore mental capabilities in old mice, which could spell a new paradigm for recharging aging brains. 

Gene variant puts women at higher risk of Alzheimer’s than it does men, study finds

Carrying a copy of a gene variant called ApoE4 confers a substantially greater risk for Alzheimer's disease on women than it does on men, researchers have found.